Cohort Study for Gastric MALT Lymphoma

Establishment of a Cohort for Investigating the Pathophysiology of Gastric MALT Lymphoma

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06454149

Acronym

HUG-MALToma

Enrollment

300

Registered

2024-06-12

Start date

2024-06-06

Completion date

2031-06-05

Last updated

2024-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric MALT Lymphoma

Brief summary

The goal of this observational study is to establish clinical data and tissue repository in patients with gastric MALT lymphoma and controls. Participants will be asked to provide clinical information and various tissues (saliva, gastric mucosa, and feces).

Interventions

OTHERMALT lymphoma

New diagnosis with gastric MALT lymphoma

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

\[MALT lymphoma group\] * Newly diagnosed as gastric MALT lymphoma \[Control group\] * Patients who underwent 1. diagnosed upper endoscopy for dyspepsia and had chronic gastritis, 2. therapeutic upper endoscopy for gastric hyperplastic polyps, or 3. screening upper endoscopy without any symptoms.

Exclusion criteria

* History of gastric or other malignancy * Use of antibiotics or probiotics within 4 weeks * Uncontrolled chronic illnesses

Design outcomes

Primary

Measure	Time frame	Description
Remission of gastric MALT lymphoma	Within 3 years from diagnosis	Remission of gastric MALT lymphoma

Secondary

Measure	Time frame	Description
Eradication of H. pylori infection	Within 6 month from eradication therapy	Eradication of H. pylori infection

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026